异丙托溴铵与无创通气治疗慢性阻塞性肺疾病
Ipratropium bromide and noninvasive ventilation treatment for COPD.
作者信息
Lin Sheng, Li Xiaoqin, Xie Baosong, Yue Wenxiang, Yao Xiujuan, Lin Ming
机构信息
Department of Respiratory and Critical Care Medicine, Fujian Provincial Hospital, Fujian Provincial Clinical Medical College, Fujian Medical University Fuzhou 350001, Fujian Provincial, China.
出版信息
Am J Transl Res. 2022 May 15;14(5):3319-3326. eCollection 2022.
OBJECTIVE
To explore the effects of ipratropium bromide combined with non-invasive ventilation for patients with both chronic obstructive pulmonary disease (COPD) and respiratory failure.
METHODS
A total of 110 patients with both COPD and respiratory failure who were admitted to our hospital from April 2018 to August 2019 were enrolled in this study; of which 52 patients were treated with a noninvasive ventilator as Group A, and the rest were treated with ipratropium bromide combined with noninvasive ventilation as Group B. The two groups were compared for blood gas indexes, pulmonary function, and treatment efficacy, and adverse reactions.
RESULTS
After treatment, Group B showed better blood gas indexes and pulmonary function than Group A (both < 0.05), and Group B also showed significantly lower levels of inflammatory factors than Group A ( < 0.05). In addition, the efficacy and life quality of Group B were better than those of Group A, and adverse reactions of Group B were less than those of Group A (all < 0.05).
CONCLUSION
Ipratropium bromide combined with noninvasive ventilation is effective in the treatment of patients with both COPD and respiratory failure.
目的
探讨异丙托溴铵联合无创通气对慢性阻塞性肺疾病（COPD）合并呼吸衰竭患者的影响。
方法
选取2018年4月至2019年8月我院收治的110例COPD合并呼吸衰竭患者纳入本研究；其中52例患者采用无创呼吸机治疗作为A组，其余患者采用异丙托溴铵联合无创通气治疗作为B组。比较两组患者的血气指标、肺功能、治疗效果及不良反应。
结果
治疗后，B组血气指标和肺功能均优于A组（均P<0.05），B组炎症因子水平也显著低于A组（P<0.05）。此外，B组的治疗效果和生活质量均优于A组，且B组不良反应少于A组（均P<0.05）。
结论
异丙托溴铵联合无创通气治疗COPD合并呼吸衰竭患者有效。
Zotero 插件